BiotechTube

Valbenazine + Placebo

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obsessive-Compulsive Disorder

Conditions

Obsessive-Compulsive Disorder

Trial Timeline

Feb 1, 2026 → Dec 1, 2027

NCT ID
NCT07111988

About Valbenazine + Placebo

Valbenazine + Placebo is a phase 2 stage product being developed by Neurocrine Biosciences for Obsessive-Compulsive Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07111988. Target conditions include Obsessive-Compulsive Disorder.

What happened to similar drugs?

2 of 4 similar drugs in Obsessive-Compulsive Disorder were approved

Approved (2) Terminated (0) Active (2)
✅pregabalin + PlaceboPfizerApproved
✅Escitalopram + Placebo oral tabletLundbeckApproved
🔄Troriluzole + PlaceboBiohavenPhase 3
🔄Troriluzole + PlaceboBiohavenPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07111988Phase 2Recruiting
NCT05654870Phase 3Terminated
NCT04102579Phase 3Completed

Competing Products

8 competing products in Obsessive-Compulsive Disorder

See all competitors
ProductCompanyStageHype Score
Bitopertin + Placebo + SSRIRochePhase 2
35
pregabalin + PlaceboPfizerApproved
43
Sertraline + Levetiracetam + PlaceboUCBPhase 2/3
30
Escitalopram + Placebo oral tabletLundbeckApproved
44
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 2/3
32
Nitrous Oxide + NitrogenBrain BiotechPhase 2
32